CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: However, when examining the most primitive and clinically relevant CML population (CD34+CD38−), there was a marked reduction in both the percentage and absolute number of human CML LSCs following treatment with MSDC-1060 (Fig. 6c, Supplementary Fig. S6D).